Combination treatment before and after surgery for stomach cancer

Plain-English translation of NCT07026149 on ClinicalTrials.gov ↗ · Source last updated June 2025 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination approach to treat advanced stomach cancer that hasn't been treated before. The study combines radiation therapy, traditional chemotherapy drugs (S-1 and oxaliplatin), and two newer medications called apatinib and camrelizumab — given both before surgery to shrink the tumor and after surgery to help prevent it from returning.

Advanced stomach cancer is difficult to treat and many people experience cancer recurrence even after surgery. This trial exists to see whether using this combination of radiation, chemotherapy, and newer immunotherapy and targeted medications can help more people survive longer and reduce the chance the cancer comes back.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced gastric or gastroesophageal junction adenocarcinoma that has not been treated before
your cancer is considered resectable, meaning doctors believe surgery can remove it
you are healthy enough to tolerate chemotherapy and radiation (ECOG performance status 0–1)
you have adequate organ function (liver, kidney, heart, and blood counts are healthy enough)
you have a life expectancy of greater than 12 months
you are willing to use contraception during treatment and for 120 days after if you can become pregnant

You likely don't qualify if…

you have uncontrolled high blood pressure (systolic ≥140 mmHg or diastolic ≥90 mmHg) despite taking blood pressure medications
you have a known allergy or hypersensitivity to any of the study drugs
you have bleeding or clotting disorders (such as hemophilia, thrombocytopenia, or coagulation disorders)
you have an inherited or acquired weakened immune system (such as HIV infection)
you have received prior treatment for your gastric or gastroesophageal junction cancer

What participation looks like

If you join this trial, you would receive radiation therapy combined with chemotherapy and the two newer medications before your surgery to help shrink the tumor. After surgery, you would continue receiving the same treatment after surgery to help prevent recurrence. Throughout the study, you'll have regular clinic visits for check-ups, blood tests, and imaging scans to monitor how you're responding and manage any side effects. The entire treatment period spans several months, with follow-up visits continuing afterward.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Trial locations(1 site)

China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality